{"product_id":"clinical-dilemmas-in-inflammatory-bowel-disease-9781444334548","title":"Clinical Dilemmas in Inflammatory Bowel Disease","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThe second edition of \u003ci\u003eClinical Dilemmas in Inflammatory Bowel Disease: New Challenges\u003c\/i\u003e, is a practical, up-to-date handbook providing expert guidance on specific clinical dilemmas and areas of difficulty that the gastroenterologist regularly faces in day-to-day practice.  \u003cp\u003eIn this new edition, 75% of the dilemmas are brand new dilemmas facing the IBD specialist concerning emerging treatment therapies, such as the use of cannabinoids and Viagra for Crohn's disease. The remaining 25% of the dilemmas are fully updated from the previous edition, incorporating the latest clinical thinking.\u003c\/p\u003e \u003cp\u003eEach of the 57 evidence-based chapters contains clear learning points, addresses different topics, and provides sound guidance on subjects ranging from optimizing current management through to special management problems and novel treatments.\u003c\/p\u003e \u003cp\u003eThis book is suitable for all medical professionals involved in the care of patients with IBD: established and trainee gastroenterologists, col\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003e\u003cb\u003e“\u003c\/b\u003eBottom Line\u003cb\u003e:\u003c\/b\u003e Clinical Dilemmas in Inflammatory Bowel Disease: New Challengestargets the IBD clinician and is a practical, well-written, easy-to-use text that will be invaluable to all involved in the care of IBD patients, including gastroenterologists, nurses, colorectal surgeons, and dieticians.  Trainee gastroenterologists will find this text useful both in IBD management and as a source for IBD clinical presentations.  I highly recommend this text for anyone who is engaged in the day-to-day clinical care of patients with IBD.”  (\u003ci\u003eGastroenterology\u003c\/i\u003e, 1 December 2012)\u003c\/p\u003e \"This is a timely update and expanded second edition that examines many newer clinical dilemmas in IBD. The short chapters are easy to absorb and key opinion leaders offer interesting insights. It certainly justifies replacing the previous edition.\" (Doody's, 24 February 2012)\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eList of Contributors.  \u003cp\u003ePreface.\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 1: Genes and Phenotype in IBD.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Which will take us further in IBD – study of coding variation or epigenetics? (\u003ci\u003eMiles Parkes\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e2 IBD in different ethnic groups: same or different? (\u003ci\u003eRupert W.L. Leong, Dorothy K.L. Chow and Christian P. Selinger\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 2: Bugs and IBD – good, bad or indifferent?\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e3 How does the risk of infection influence management of IBD around the world? (\u003ci\u003eKiran K. Peddi and Ian Craig Lawrance\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e4 Travelling with IBD (\u003ci\u003eIng Shian Soon and Gilaad Kaplan\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e5 What to do about hepatitis B and hepatitis C in patients with IBD (\u003ci\u003eMorven Cunningham and Graham R. Foster\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e6 CMV in IBD – passenger or pathogen? (\u003ci\u003eAhmed Kandiel \u0026amp; Bret Lashner\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e7 Clostridium difficile in IBD: Impact, Prevention and Treatment (\u003ci\u003eAshwin N. Ananthakrishnan and David G. Binion\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e8 Pre- and synbiotics: placebo or panacea (\u003ci\u003eJames O. Lindsay\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e9 Worms – light at the end of their burrow? (\u003ci\u003eJohn Leung and Joel V. Weinstock\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e10 Do we really need to vaccinate all patients with IBD? (\u003ci\u003eGauree Gupta and Gil Y. Melmed\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 3: Investigating IBD.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e11 Biomarkers in IBD: myth or marvel? (\u003ci\u003eRichard B. Gearry, Andrew S. Day\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e12 Radiation exposure in IBD: how do we minimize the dangers? (\u003ci\u003eOwen J O'Connor, Alan N. Desmond, Fergus Shanahan and Michael M. Maher\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e13 Surveillance colonoscopy in UC – what’s the best way to do it? (\u003ci\u003eMatt Rutter\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 4: Medical therapy.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5-ASA.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e14 New 5ASAs: a tiny step or giant stride forward? (L. Campbell Levy).\u003c\/p\u003e \u003cp\u003e15 Do 5ASAs prevent cancer? (\u003ci\u003eRichard Logan and Venkataraman Subramanian\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e16 Why do we still use 5-ASAs in Crohns disease? (\u003ci\u003eStephen Hanauer, Henit Yanai, Emma Calabrese\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSteroids.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e17 Steroids in Crohn's disease: do the benefits outweigh the dangers? (\u003ci\u003eA. Hillary Steinhart\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003eImmunomodulators.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e18 Thioguanine nucleotide measurement: Non-adherent, shunter, under-dosed or resistant? (\u003ci\u003eMiles Sparrow\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e19 Thiopurines and the sun: what should be done? (\u003ci\u003eConal M. Perrett, Jane M. McGregor, Catherine A. Harwood\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e20 Do thiopurines worsen risk and prognosis of cervical neoplasia? (\u003ci\u003eJeremy D. Sanderson and Melissa A. Smith\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e21 Optimising use of methotrexate (\u003ci\u003eAnna Foley and Peter R. Gibson\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e22 Which calcineurin inhibitor and when? (\u003ci\u003eA. Barney Hawthorne\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003eBiologics.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e23 Are all anti-TNF agents the same? (\u003ci\u003eJennifer L. Jones\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e24 One drug or two: Do patients on biologics need concurrent immunomodulation? (\u003ci\u003eGlen A. Doherty and Adam S. Cheifetz\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e25 How do we identify patients needing early aggressive therapy and what should we use? (\u003ci\u003eMarc Ferrante and Séverine Vermeire\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e26 What is the role of biologics in UC? (\u003ci\u003eJoanna K. Law and Brian Bressler\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e27 What can we do with Crohn's patients refractory to antiTNF therapy? (\u003ci\u003eDavid T. Rubin\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e28 Which EIMs respond to biologics? (\u003ci\u003eTina A. Mehta and CS Probert\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e29 Use and abuse of biologics in pregnancy (\u003ci\u003eMarla C. Dubinsky\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e30 Is anti-TNF therapy safe to use in people with a history of malignancy? (\u003ci\u003eMark Lust and Simon Travis\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e31 What and how should we tell patients about the risks of immunomodulators and biologics? (\u003ci\u003eCorey A Siegel\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e32 When, how and in whom should we stop biologics? (\u003ci\u003eEdouard Louis, Jacques Belaiche, Catherine Reenaers\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 5: Other treatments.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e33 Avoiding drug interactions (\u003ci\u003eTim Elliott and Peter M. Irving\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e34 Is there still a role for ursodeoxycholic acid treatment in patients with inflammatory bowel disease associated with primary sclerosing cholangitis? (\u003ci\u003eEmmanouil Sinakos \u0026amp; Keith Lindor\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e35 Stem cell transplantation for Crohn's: what's the risk-benefit ratio? (\u003ci\u003eVenkataraman Subramanian and Christopher J Hawkey\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e36 Complementary Therapy: Is There a Needle in the Haystack? (\u003ci\u003eShane M. Devlin\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 6: Surgical Dilemmas in IBD.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e37 Optimising IBD patients for surgery and recovery (\u003ci\u003eJonathan Wilson and Alastair Windsor\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e38 Is surgery the best initial treatment for limited ileocaecal Crohn's disease? (\u003ci\u003eTom Øresland\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e39 Laparoscopic or open surgery for IBD? (\u003ci\u003eDonna Appleton and Michael Hershman\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e40 Perianal Crohn's disease – optimal management (\u003ci\u003eDavid A. Schwartz and Norman R. Clark III\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e41 Does anti-TNF therapy increase the risk of Complications of surgery? (\u003ci\u003eMing Valerie Lin, Wojciech Blonski and Gary R. Lichtenstein\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e42 Pouches for Indeterminate Colitis and Crohn's Disease: Act Now, Pay Later? (\u003ci\u003ePhillip Fleshner\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e43 Dealing with pouchitis (\u003ci\u003eBo Shen and Simon McLaughlin\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 7: Unsolved issues in IBD.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e44 Mucosal healing in IBD – does it matter? (\u003ci\u003eGeert D'Haens\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e45 Vitamin D in IBD: from genetics to bone health via cancer and immunology (\u003ci\u003eHelen M. Pappa and Richard J. Grand\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e46 Got Milk? Medication Use and Nursing in Women with IBD (Sunanda Kane).\u003c\/p\u003e \u003cp\u003e47 Does stress matter? (\u003ci\u003eRobert Maunder\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e48 IBS is common in IBD: fact or fallacy? (\u003ci\u003eJames Goodhand \u0026amp; David Rampton\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e49 So where is all the cancer? (\u003ci\u003eJudith E. Baars \u0026amp; C. Janneke van der Woude\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 8: Nutrition in IBD.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e50 What should patients with IBD eat? (\u003ci\u003eEmile Richman, Keith Leiper, Jonathan Rhodes\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e51 Enteral Nutrition in Crohn's - Who for, When, How and Which Formula? (\u003ci\u003eR. Shamir and Ernest G. Seidman\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e52 Optimizing treatment of iron deficiency anemia (\u003ci\u003eHermann Schulze and Axel Dignass\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 9: Management process.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e53 IBD Standards: will they enhance patient care? (\u003ci\u003eMichael D. Kappelman\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e54 Your treatment won’t work if the patient doesn't take it (\u003ci\u003eRob Horne\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e55 Inflammatory Bowel Disease: What to tell your ED team (\u003ci\u003eLouise Langmead\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e56 Transitioning from pediatric to adult care (\u003ci\u003eElizabeth J. Hait and Laurie N. Fishman\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e57 Medicolegal Pitfalls in Inflammatory Bowel Disease (IBD) Care (\u003ci\u003eWilliam J. Tremaine\u003c\/i\u003e).\u003c\/p\u003e","brand":"John Wiley and Sons Ltd","offers":[{"title":"Default Title","offer_id":49408387907927,"sku":"9781444334548","price":64.55,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781444334548.jpg?v=1730502717","url":"https:\/\/bookcurl.com\/products\/clinical-dilemmas-in-inflammatory-bowel-disease-9781444334548","provider":"Book Curl","version":"1.0","type":"link"}